Sign in
Enrolling by invitationNo phase

Periodic over-the-counter glucose sensors for adults with type 2 diabetes not using insulin

Tests wearing a glucose sensor every 30 or 90 days in type 2 diabetes.

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Registry title
T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking
Status
Enrolling by invitation
People taking part
188 people, planned
Started
2 Apr 2026
Expected to end
Jun 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Periodic, over-the-counter continuous glucose monitoring
Record updated
29 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who do not use insulin and get care at a taking-part primary care practice. It tests wearing a glucose sensor now and then.

Age
18 years or older
Sex
All sexes can join
Disease stage
Type 2 diabetes with an A1C of 6.5 or higher in the 6 months before joining
Earlier treatment
No use of a real-time or flash glucose sensor in the 12 months before joining. No insulin in the 12 months before screening. Glucose-lowering or weight loss medicines kept stable for 30 days before joining.
Biomarker or test result
A1C value of 6.5 or higher (from lab data or chart review) in the 6 months before joining

Main reasons for not taking part

  • Used insulin in the past 12 months or plans to start insulin in the next 12 months
  • End stage kidney disease on dialysis, or eGFR below 30 mL/min/1.73m2
  • Pregnant or planning to become pregnant in the next 6 months
  • Using hydroxyurea, or a blood condition that affects A1C measurement
  • Severe allergy to medical adhesive, a serious skin condition, or extensive tattoos that block sensor placement

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age ≥ 18 years at time of enrollment
  • Diagnosis of type 2 diabetes
  • Able to read and understand English (Dexcom Stelo is currently only available in English)
  • No real-time or intermittently scanned (Flash) CGM use 12 months prior to enrollment
  • Stable medication regimen (medication classes) and dose (equivalent dose if medication has been changed within the same medication class) for any glucose lowering or weight loss medications for 30 days prior to enrollment and willing to not change medications prior to randomization unless safety concerns
  • Cell phone meeting minimum required OS compatibility with Stelo
  • Willing to use the study device and download the Stelo app
  • Willing and able to complete all study procedures per investigator discretion, including willingness to accept either experimental group (q30 or q90)
  • A1C value (from lab data or chart review) greater than or equal to 6.5 in the 6 months prior to enrollment
  • Currently receiving primary care in a participating study practice

Who cannot take part

  • Use of insulin in the 12 months prior to screening or planning to initiate insulin during the next 12 months (short-term use of insulin in an inpatient setting is acceptable)
  • Concomitant disease or condition that in the opinion of the investigator may compromise patient safety including but not limited to severe mental illness, a diagnosed or suspected eating disorder, or any uncontrolled or chronic medical condition that would interfere with study related tasks or visits
  • Known presence of a hemoglobinopathy or other condition that is expected to affect the measurement of A1C in the judgment of the investigator
  • Known severe allergy to medical grade adhesive, a serious skin condition that could interfere with CGM placement, or extensive tattoos that precludes the use of CGM in an FDA approved location
  • Use within 30 days of screening visit of any medication that in the opinion of the investigator may exacerbate glucose dysfunction (e.g. systemic corticosteroids)
  • End stage renal disease currently managed by dialysis or eGFR <30 mL/min/1.73m2
  • Current or planned use of hydroxyurea (due to interference with CGM)
  • Current participation in another interventional study protocol that could impact participation in this study per investigator discretion
  • Pregnant or planning to become pregnant within the next 6 months
  • Planning to switch primary care practices in the next 6 months

Where in United States

  • University of Colorado Denver - Anschutz Medical CampusAurora, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if periodic use of over-the-counter continuous glucose monitoring (CGM) can support glucose management in people with type 2 diabetes not using insulin being treated in primary care settings. The main questions it aims to answer are:

Read full original descriptionShow less

* Is periodic use of CGM every 30 or 90 days for six months associated with reduced A1C compared to usual care at baseline? * Is periodic use of CGM every 30 or 90 days for six months associated with increased time in range and time in tight range compared to usual care at baseline? * Is periodic use of CGM every 90 days over six months associated with non-inferior A1C reduction compared to periodic use of CGM every 30 days? * Are clinician feasibility and acceptability of periodic, OTC CGM higher than for prescription CGM? * How acceptable is periodic, OTC CGM to people with non-insulin-treated type 2 diabetes? Researchers will compare use of periodic CGM every 30 and 90 days to see if less frequent periodic CGM use can support glucose management as effectively as more frequent use.

Participants will:

* be assigned to one of two groups using the 15-day Dexcom Stelo® glucose biosensor every 30 or 90 days over a six-month period. * receive Stelo devices every 30 or 90 days (as randomized) * complete up to 9 virtual or in-person visits with the study team. * complete 3 fingerstick A1c tests. * wear a blinded CGM device at 3 time points outside of Dexcom Stelo® use. * complete a survey at the end of the study.

The 2 groups in the trial

  • 30 dayTreatment being tested

    Use of periodic, OTC CGM every 30 days for six months.

    Treatment: Periodic, over-the-counter continuous glucose monitoring

  • 90 dayTreatment being tested

    Use of periodic, OTC CGM every 90 days for six months.

    Treatment: Periodic, over-the-counter continuous glucose monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Improving Type 2 Diabetes Management in Primary Care Through Periodic Continuous Glucose Monitoring
Plain-language title
Periodic over-the-counter glucose sensors for adults with type 2 diabetes not using insulinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
29 April 2026